Across sub-Saharan Africa, patients with HIV on antiretrovirals often get malaria and need co-26 treatment with artemisinin-containing therapies. We undertook two pharmacokinetic studies in 27 healthy volunteers, using standard adult doses of artmether-lumefantrine (AL) or artesunate-28 amodiaquine (AS-AQ) given with 50mg once daily dolutegravir (DTG) to investigate the drug-29 drug interaction between artmether-lumefantrine or artesunate-amodiaquine and DTG. The 30 DTG/artmether-lumefantrine interaction was evaluated in a two-way cross-over study and 31 measured artemether (ARM), dihydroartemisinin (DHA), lumefantrine (LF), desbutyl-32 lumefantrine (DBL) over 264h. The DTG/artesunate-amodiaquine interaction was investigated 33 using a parallel study design due to long half-life of the amodiaquine metabolite, 34 desethylamodiaquine (DEAQ) and measured artesunate (ARS), amodiaquine (AQ), DEAQ over 35 624h. Non-compartmental analysis was performed, and geometric mean ratios and 90% 36 confidence intervals generated for evaluation of both interactions. Dolutegravir did not 37 significantly change the maximum concentration in plasma, time to maximum concentration and 38 area under the concentration-time curve (AUC) for ARM, DHA, LF and DBL nor significantly 39 alter AUC for ARS, DHA, AQ and DEAQ. Co-administration of dolutegravir with AL resulted in a 40 37% decrease in DTG trough concentrations. Co-administration of dolutegravir with AS-AQ 41 resulted in a decrease of approximately 42% and 24% in DTG trough concentrations and AUC 42 respectively. Study drugs were well-tolerated with no serious adverse events. Standard doses of 43 artmether-lumefantrine and artesunate-amodiaquine should be used in patients receiving DTG. 44 The significant decreases in DTG trough concentrations with artemether-lumefantrine and 45 artesunate-amodiaquine and DTG exposure with artesunate-amodiaquine are unlikely to be of 46 clinical significance as DTG trough concentrations were above DTG target concentrations of 3 Abstract word count: 250 (max 250) 51 52 INTRODUCTION 53 Over 90% of malaria cases occur in sub-Saharan Africa (SSA) the region with the greatest 54 burden of HIV(1). Drug-drug interactions (DDIs) between antiretrovirals and artemisinin-based 55 combination therapies (ACT) frequently occur and may affect the clinical effectiveness of 56 commonly utilized antimalarials artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-57 AQ)(2-4).The likely adoption of dolutegravir (DTG) in preferred first-line antiretroviral therapy 58 (ART) regimens(5) makes a DDI study with antimalarials an urgent priority. Dolutegravir is 59 predominately metabolized via uridine diphosphate glucuronyl transferase 1A1 (UGT 1A1) with 60 minor input from cytochrome P450 (CYP)-3A4(6). 61 Both artemether (ARM) and lumefantrine (LF) are predominantly metabolized via CYP3A4, 62 CYP2B6, CYP2C9 and CYP2C19 to active metabolites dihydroartemisinin (DHA) and desbutyl-63 lumefantrine (DBL) respectively. Artesunate (AS) is a prodrug and substrate of CYP2A6 and 64 undergoes rapid hydrolysis to DHA while amodiaquine (AQ) is extensively metabolized by CYP 65 2C8 to its active metabolite, N-desethylamodiaquine (DEAQ)(5,7). Co-administration of 66 artemether-lumefantrine with inducers of CYP3A4 results in significant reductions in artemether 67 and dihydroartemisinin exposures(8). Similarly, clinically significant DDIs with ritonavir-boosted 68 protease inhibitor ART regimens have been reported(3). However, data for dolutegravir are 69 lacking. We investigated the pharmacokinetic (PK) interactions between dolutegravir with 70 artemether-lumefantrine or artesunate-amodiaquine and assessed safety and tolerability of the 71 drug combinations. 72 4 73 METHODS 74 Ethics: The study was approved by the Joint Clinical Research Centre Institutional Review 75 Board, Kampala, Uganda and University of Liverpool Research Ethics Committee, Liverpool, UK 76 and registered on ClinicalTrials.gov (NCT 02242799). The study was conducted in compliance 77 with International Council for Harmonisation Good Clinical Practice guidelines, the current 78 ethical principles in the Declaration of Helsinki and applicable local regulatory requirements. 79 Study Design: Two open-label, fixed sequence studies between DTG and artemether-80 lumefantrine (Study A), or artesunate-amodiaquine (Study B) were conducted at the Infectious 81 Diseases Institute, Kampala, Uganda. Inclusion of 16 subjects in Study A was calculated to 82 have a >80% power to detect a change in area under the concentration-time curve (AUC) 83 outside FDA limits for bioequivalence for dolutegravir and lumefantrine (assuming coefficient of 84 variation ≤30%), and to detect a ≥32% change in dihydroartemisinin levels. Including 30 85 subjects in Study B would yield an 80% power to detect an AUC difference of >25-30% (DTG 86 and DEAQ), and a ≥42% change for dihydroartemisinin. 87
64ng/mL.
Pharmacokinetic analysis 121
Dolutegravir blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes (9) . 122
Samples for artemisinin-based combination therapies were collected in either lithium heparin or 123 fluoride-oxalate tubes to minimize ex-vivo degradation of artemisinins to DHA by plasma 124 esterases(10). Blood samples were delivered within 15 minutes of collection to the laboratory for 125 separation and storage at -80ºC until shipment to the Liverpool Bioanalytical Facility and 126
Mahidol University for quantification of dolutegravir and ACTs, respectively. Both laboratories 127 participate in external Quality Assurance programmes and operate to GCP with assays 128 validated according to published FDA guidelines. 129
Dolutegravir was extracted using liquid-liquid extraction and analyzed using a validated 130 reversed phase liquid chromatography with a lower limit of quantification (LLOQ) set at 10 ng/ml 131 and precision of 5% at low QC (30ng/mL) (9) . 132
Antimalarial drugs were extracted using solid-phase extraction, and quantified by liquid 133 chromatography tandem-mass spectrometry (LC-MS/MS). For artemether/dihydroartemisinin 134 the total assay coefficient of variation was < 6% with LLOQ of 1.14 ng/ml. For artesunate/ 135 dihydroartemisinin the coefficient of variation was < 7% with LLOQ of 0.119 ng/ml (AS) and 136 0.196 ng/ml (DHA)(10). For lumefantrine/desbutyl-lumefantrine total coefficient variation was 137 <6% with LLOQ of 7.77 ng/ml (LF) and 0.81 ng/ml (DBL)(11). For amodiaquine/N-138 desethylamodiaquine the total coefficient of variation was <8% with LLOQ of 0.86 ng/ml (AQ) 139 and 1.13 ng/ml (DEAQ). 140
Statistical analysis 141
Pharmacokinetic parameters including the area under the concentration-time curve to the last 142 measurable time point (AUC 0-t ), terminal elimination half-life (t 1/2 ), maximum concentration (C max ) 143
and time to C max (T max ) were estimated using non-compartmental analysis (WinNonlin, Phoenix, version 6.1, Pharsight, Mountain View, CA). PK data were log-transformed to calculate 145 geometric mean ratios (GMR), with 90% CI evaluated using paired (Study A) or unpaired (Study 146 B) t-tests and back-transformed to absolute ng/mL concentrations. An analysis of variance 147 (ANOVA) was performed by SPSS (Windows Standard version 22; SPSS, Inc., Chicago, IL) on 148 PK parameters (AUC 0-t , C max , C 24 ) using generalized linear models procedures to assess 149 potential sequence and period related effects. 150
151

RESULTS 152
Forty-eight participants were enrolled into both studies of whom 39 completed study procedures. 153
Demographic variables of participants who completed study procedures are presented in Table  154 1. 155
Antimalarial Pharmacokinetics 156
Effect of dolutegravir on artemether-lumefantrine pharmacokinetics (Study A) 157
In study A, 14 participants received AL (7 Arm 1; 7 Arm 2). The artemether/dihydroartemisinin 158 PK profiles (0-24 hours), lumefantrine/desbutyl-lumefantrine PK profiles (0-264 hours), and 159 associated PK parameters are presented in Table 2 . 160
When artemether-lumefantrine was administered alone, geometric mean (GM 90% CI) 161 artemether maximum concentrations of 31.9 ng/ml (20.6-43.2) were reached on average in 2 162 hours, with AUC 0-t of 129.6 ng.h/ml (79.4-179.8). The active metabolite DHA achieved peak 163 concentrations of 110.4 ng/ml (92.9-128.0) after 2.3 hours with AUC 0-t of 389.3 ng.h/ml (344.5-164 434.0). Artemether and dihydroartemisinin were eliminated from plasma with an average half-165 life of 5 and 2.5 hours, respectively. 166
Lumefantrine showed peak concentrations approximately four hours after drug administration, 167 with a C max and AUC 0-t of 9976 ng/ml (8318-11633) and 389350 ng.h/ml (333608-445092), respectively. The lumefantrine metabolite DBL had a C max and AUC 0-t of 51.7 ng/ml (37.5-66.0) 169 and 6699 ng.h/ml (4804-7796) respectively, representing approximately 1.7% of total circulating 170 lumefantrine. The elimination half-life of lumefantrine and desbutyl-lumefantrine were 83 and 171 142 hours, respectively. 172
The GMR for each antimalarial and metabolite are presented in Table 2 . Co-administration of 173 artemether-lumefantrine with DTG did not significantly alter C max , AUC 0-t or clearance of 174 artemether, lumefantrine or their metabolites. Furthermore, the time of the last measurable 175 concentration (t) for all artemether-lumefantrine components did not significantly differ when 176 administered alone or in combination with DTG. The analysis of variance (ANOVA) showed no 177 evidence of a significant sequence or period effect upon artemether-lumefantrine PK. 178
In study B, 25 participants received AS-AQ. 13 subjects in Arm 1 were administered artesunate-181 amodiaquine alone, and 12 subjects in Arm 2 were administered artesunate-amodiaquine with 182 DTG. The artesunate/ dihydroartemisinin PK profiles (0-12 hours), amodiaquine/N-183 desethylamodiaquine PK profiles (0-624 hours), and associated PK parameters are presented 184
in Table 2 . 185
When artesunate-amodiaquine was administered alone, maximum artesunate concentrations of 186 61.3 ng/ml (41.5-81.0) were reached within 1.2 hours, with an overall AUC 0-t of 128.4 ng.h/ml 187 (90.8-165.9). Dihydroartemisinin exposures were on average 6-fold higher than corresponding 188 artesunate AUC 0-t values. Artesunate and dihydroartemisinin geometric mean half-life was 1.9 189 and 2.2 hours, respectively. Similarly, amodiaquine was rapidly absorbed (T max = 2.4 hours) and 
Effect of artemether-lumefantrine on dolutegravir pharmacokinetics (Study A) 205
In study A, dolutegravir C max of 5018 ng/ml (4512-5525) was reached at 3.9 hours post-dose, 206
with an overall AUC 0-24 of 78753.4 ng.h/ml (70615-86891). 207
Co-administration of DTG with artemether-lumefantrine resulted in a 37% decrease in 208 dolutegravir C 24 [GMR = 0.63 (0.48-0.82)]. No significant changes were observed in dolutegravir 209 AUC 0-24 or C max when DTG was administered with artemether-lumefantrine ( Table 2 ). The 210 ANOVA revealed no significant sequence effect upon dolutegravir PK. However, there was a 211 significant period effect (DTG alone vs. DTG + AL) for dolutegravir C 24 in both arms (p=0.025). 212
Co-administration of DTG with artesunate-amodiaquine resulted in a significant decrease of 217 approximately 42% and 24% in dolutegravir C 24 and AUC 0-24 , respectively as presented in Table  218 2. 219 prior to the last sampling point at 24 hours was unlikely, as subjects were instructed not to take 241 the next dose before this time-point, and were issued with an exact number of pills which 242 precluded such additional intake. 243
244
With artesunate-amodiaquine, we observed an unexplained statistically significant reduction of 245 42% and 24% for dolutegravir C 24 and AUC 0-24 respectively. However, in all subjects who 246 received DTG with artemether-lumefantrine or artesunate-amodiaquine, the dolutegravir C trough 247 was comparable to or above 1100ng/mL, the mean C trough observed in prior dolutegravir phase 3 248 adults trials. The target minimum effective concentrations for dolutegravir are unknown, 249 although a DTG protein-adjusted IC 90 of 64ng/mL has been proposed. In a phase II study, C trough 250 concentrations over 324ng/mL after 10 days of DTG monotherapy were associated with 251 virological efficacy(12). All subjects in our study had C trough concentrations exceeding these 252 targets, suggesting that the modest pharmacokinetic changes observed have unlikely clinical 253 significance, especially given the short duration of antimalarial therapy. 254
255 Surprisingly, dolutegravir concentrations in this study of black African healthy volunteers were 256 somewhat higher than previously reported in Caucasians. It should be noted that dolutegravir 257 was dosed with a moderate fat meal, and concentrations observed are consistent with reports 258 on the food effect upon DTG bioavailability(13). 259
The combination of dolutegravir with artemether-lumefantrine and artesunate-amodiaquine was 260 well tolerated. Nausea, the most common study drug-related adverse event, was reported 261 predominately in the artesunate-amodiaquine arm. This safety profile was consistent with the 2.
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Byakika 15 h (7.95, 10.34) AS alone, 7.44 h (6.22, 8.67) AS + DTG; 11.63 h (11.12, 12.14) DHA alone, 11.60 h (11.05, 12.15) DHA + DTG; 69.16 h (63.74, 74.58) AQ alone, 60.81 (54.92, 66.69) AQ + DTG, 624 h DEAQ alone, 509.96 h (430.24, 589.68 AS-AQ alone (Arm 1) AS-AQ + DTG (Arm 2)
